Assertio Holdings, Inc.
NASDAQ:ASRTDrug Manufacturers - Specialty & Generic
+$0.01 today
- Market cap
- $151.86M
- Beta
- 0.53
- P/E (TTM)
- -4.2
- EPS (TTM)
- -$5.55
Volume 0.27M
Average 0.33M
ASRT Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Assertio Holdings, Inc.NASDAQ: ASRT
Operating Income · Q1 FY2026 · quarter ended Mar 2026
Operating income remains negative
Q1 FY2026 operating income was -$18.47M, compared with -$12.94M a year earlier. Trailing-twelve-month operating income was -$22.75M.
Context
- Operating income amounted to 14.5% of revenue in FY2025, down 5.1 pp from a year earlier.
- Operating income increased in 2 of the last 3 fiscal years.
What to watch
Whether operating income reaches the consensus estimate from 3 analysts of $4.71M (+127.4%) for the fiscal year ending Dec 2026, a step up from the +29.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$18.47M-101.9% QoQ
- Last fiscal yearDec 2025
- -$17.22M+29.6% YoY
- LTMMar 2026
- -$22.75M+31.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -42.7% | +115.3% | +158.0 pp |
| 1 year | +29.6% | +127.4% | +97.7 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (17.22M) USD
- Year-over-year change
- +29.6%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (17.22M) | +29.6% |
| FY2024 | 2024-12-31 | (24.48M) | +89.9% |
| FY2023 | 2023-12-31 | (243.54M) | -718.0% |
| FY2022 | 2022-12-31 | 39.41M | +318.1% |
| FY2021 | 2021-12-31 | 9.42M | — |
Operating Income vs competitors
How ASRT compares with its peers on the latest reported figures
- Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +31.2% is the 3rd highest of 10, against a peer median of +7.9%.
- Operating income amounts to 22.3% of revenue for ASRT, versus a peer median of 71.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $38.18M USD | +166.8% | — | 14.9% | |
| LTM Apr 2026 | -$8.16M USD | -31.3% | — | 452.6% | |
| LTM Mar 2026 | -$22.75M USD | +31.2% | — | 22.3% | |
| LTM Mar 2026 | -$48.41M USD | -7.2% | — | — | |
| LTM Mar 2026 | -$52.06M USD | +9.8% | — | 58.8% | |
| LTM Mar 2026 | -$55.81M USD | +43.9% | — | 84.4% | |
| LTM Jun 2025 | -₪72M ILS | -68.2% | -49.0% | 29.6% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$82.35M USD | +11.6% | — | — |
| LTM Mar 2026 | -$83.66M USD | +5.8% | — | — | |
| LTM Mar 2026 | -$128.7M USD | +7.9% | — | 1408.7% | |
| Peer median (excluding ASRT) | — | +7.9% | -49.0% | 71.6% | |
Competitors are the stored peer set for ASRT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 111.01M | 156.23M | 152.07M | 124.96M | 118.71M |
| Cost of Revenue | 15.83M | 18.75M | 27.02M | 39.23M | 65.39M |
| Gross Profit | 95.18M | 137.49M | 125.05M | 85.73M | 53.33M |
| Gross Margin | 85.7% | 88.0% | 82.2% | 68.6% | 44.9% |
| Research & Development | 0 | 0 | 2.84M | 3.82M | 1.69M |
| Selling, General & Admin | 56.56M | 48.1M | 69.74M | 76.95M | 68.86M |
| Operating Expenses | 85.76M | 98.08M | 368.59M | 110.21M | 70.55M |
| Depreciation & Amortization | 29.11M | 33.4M | 28.23M | 25.83M | 30.01M |
| EBITDA | 38.78M | 90.17M | 53.17M | 5.15M | 3.14M |
| EBITDA Margin | 34.9% | 57.7% | 35.0% | 4.1% | 2.6% |
| Operating Income | 9.42M | 39.41M | (243.54M) | (24.48M) | (17.22M) |
| Operating Margin | 8.5% | 25.2% | -160.1% | -19.6% | -14.5% |
| Interest Income | 0 | 0 | 0 | 3.22M | 2.67M |
| Interest Expense | 10.22M | 7.96M | 3.38M | 3.04M | 3.08M |
| Other Income / Expenses | (9.98M) | (8.24M) | (10.52M) | 2.95M | (12.72M) |
| Income Before Tax | (553K) | 31.17M | (254.05M) | (21.53M) | (29.94M) |
| Pre-Tax Margin | -0.5% | 19.9% | -167.1% | -17.2% | -25.2% |
| Income Tax Expense | 728K | (78.46M) | 77.89M | 52K | 435K |
| Net Income | (1.28M) | 109.63M | (331.94M) | (21.58M) | (30.38M) |
| Net Margin | -1.2% | 70.2% | -218.3% | -17.3% | -25.6% |
| EPS (Basic) | (0.45) | 34.95 | (70.05) | (3.45) | (4.74) |
| EPS (Diluted) | (0.45) | 30.45 | (70.05) | (3.45) | (4.74) |
| Weighted Avg Shares | 2.88M | 3.13M | 4.74M | 6.35M | 6.4M |
| Weighted Avg Shares (Diluted) | 2.88M | 3.64M | 4.74M | 6.35M | 6.4M |
Assertio Holdings, Inc.
NASDAQ:ASRT
Intrinsic Alpha fair value
Locked
Current Price
$23.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.